鼠疫桿菌诊断市场规模、份额、成长分析，按产品、按诊断测试、按技术、按最终用户、按地区 - 产业预测 2025-2032

2023 年全球鼠疫桿菌诊断市场规模价值为 34.7 亿美元，预计将从 2024 年的 36.2 亿美元成长到 2032 年的 50.3 亿美元，预测期内（2025-2032 年）的复合年增长率为 4.2%。

预计全球鼠疫桿菌菌诊断市场将以显着的速度成长，这得益于鼠疫桿菌感染疾病盛行率的上升、诊断工具技术的进步以及公众对早期检测重要性的认识的提高。分子诊断技术的日益普及也是推动市场扩张的关键因素。此外，全球食源性疾病的爆发和鼠疫桿菌病病例的增加也加剧了市场需求。然而，诊断製造商之间的竞争加剧、政府对医疗保健的资金不足以及组织的批量采购等挑战可能会阻碍成长。北美、欧洲和亚太地区是影响市场的关键地区，在政府措施、加强医疗保健基础设施和开发创新诊断检测等的支持下，确保了未来几年的强劲成长。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术进步

鼠疫桿菌诊断市场规模（依产品划分）

• 市场概况
• 装置
• 套件和试剂

鼠疫桿菌诊断市场规模（依诊断测试）

• 市场概况
• 粪便培养
• 影像检查
• 血清学检测
• 大肠镜检查
• ELISA
• 免疫检测
• 管凝集反应
• 电脑断层扫描
• 超音波
• 大肠镜检查
• 其他的

鼠疫桿菌诊断市场规模（依技术划分）

• 市场概况
• 免疫检测
• DNA 探针
• 聚合酵素链锁反应（PCR）
• 流式细胞技术
• 层析法
• 其他的

鼠疫桿菌诊断市场规模（按最终用户划分）

• 市场概况
• 医院
• 公共卫生研究所
• 商业研究院
• 其他的

鼠疫桿菌菌诊断市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Abbott Laboratories（USA）
• Thermo Fisher Scientific（USA）
• Bio-Rad Laboratories（USA）
• Hologic, Inc.（USA）
• Becton, Dickinson and Company（BD）（USA）
• Danaher Corporation（USA）
• PerkinElmer, Inc.（USA）
• QIAGEN NV（Netherlands）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Siemens Healthineers AG（Germany）
• bioMerieux SA（France）
• Merck KGaA（Germany）
• Lonza Group AG（Switzerland）
• Agilent Technologies, Inc.（USA）
• Illumina, Inc.（USA）
• bioAffinity Technologies, Inc.（USA）
• Gen-Probe Incorporated（USA）

结论和建议

Global Yersinia Diagnostics Market size was valued at USD 3.47 billion in 2023 and is poised to grow from USD 3.62 billion in 2024 to USD 5.03 billion by 2032, growing at a CAGR of 4.2% during the forecast period (2025-2032).

The global Yersinia diagnostics market is expected to experience significant growth driven by the rising incidence of Yersinia infections, technological advancements in diagnostic tools, and heightened public awareness regarding the importance of early detection. The increasing adoption of molecular diagnostic technologies is a crucial factor propelling market expansion. Additionally, the prevalence of food-borne diseases and a rise in yersiniosis cases globally are contributing to market demand. However, challenges such as intensified competition among diagnostic producers, inadequate government funding for healthcare, and bulk procurement by organizations may hinder growth. North America, Europe, and Asia Pacific are key regions influencing the market, supported by governmental initiatives, enhanced healthcare infrastructure, and the creation of innovative diagnostic assays, ensuring robust growth in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Yersinia Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Yersinia Diagnostics Market Segmental Analysis

Global Yersinia Diagnostics Market is segmented by Product, Diagnostic Test, Technology, End User and region. Based on Product, the market is segmented into Instruments and Kits and Reagents. Based on Diagnostic Test, the market is segmented into Stool Culture, Imaging Tests, Serological Tests, Colonoscopy, ELISA, Radioimmunoassay, Tube Agglutination, CT Scan, Ultrasonography, Colonoscopy and Others. Based on Technology, the market is segmented into Immunoassay, DNA Probes, Polymerase Chain Reaction (PCR), Flow Cytometry, Chromatography and Others. Based on End User, the market is segmented into Hospitals, Public Health Laboratories, Commercial Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Yersinia Diagnostics Market

The global demand for Yersinia diagnostics is primarily driven by the increasing prevalence of Yersinia infections, particularly those caused by Yersinia enterocolitica and Yersinia pseudotuberculosis, which are notable contributors to foodborne illnesses and gastrointestinal disorders worldwide. The incidence rates of these infections fluctuate across different regions and over time; however, areas experiencing higher occurrences are generating significant needs for diagnostic solutions. Consequently, healthcare professionals and public health organizations are actively seeking reliable diagnostic tools to accurately detect and manage Yersinia infections, particularly as case numbers continue to rise, thereby fueling market growth in this sector.

Restraints in the Global Yersinia Diagnostics Market

The global Yersinia diagnostics market faces significant challenges due to the intricate nature of Yersinia infections. These infections can present a variety of nonspecific symptoms, such as diarrhea, abdominal pain, and fever, which overlap with those of other gastrointestinal disorders. This ambiguity complicates clinical diagnosis and can lead to misinterpretations, especially as Yersinia infections may also mimic conditions like appendicitis. Such difficulties in accurately and promptly identifying Yersinia infections can reduce the demand for diagnostic tests, thereby restraining market growth. Consequently, the complexity and nonspecific nature of these infections pose obstacles to effective diagnosis and treatment.

Market Trends of the Global Yersinia Diagnostics Market

The Global Yersinia Diagnostics market is experiencing a significant shift towards molecular diagnostic methods, marking a key trend in the industry. The adoption of advanced technologies like polymerase chain reaction (PCR) assays and nucleic acid amplification tests (NAATs) is on the rise, primarily due to their superior sensitivity, specificity, and reduced turnaround times compared to traditional culture-based techniques. These molecular methods enable the rapid and accurate detection of Yersinia DNA in clinical specimens, enhancing diagnostic capabilities. Consequently, healthcare providers and laboratories are increasingly investing in these advanced platforms, propelling the growth of the Yersinia diagnostics market as they strive for quicker and more reliable pathogen identification.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement

Global Yersinia Diagnostics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Instruments
• Kits and Reagents

Global Yersinia Diagnostics Market Size by Diagnostic Test & CAGR (2025-2032)

• Market Overview
• Stool Culture
• Imaging Tests
• Serological Tests
• Colonoscopy
• ELISA
• Radioimmunoassay
• Tube Agglutination
• CT Scan
• Ultrasonography
• Colonoscopy
• Others

Global Yersinia Diagnostics Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Immunoassay
• DNA Probes
• Polymerase Chain Reaction (PCR)
• Flow Cytometry
• Chromatography
• Others

Global Yersinia Diagnostics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Public Health Laboratories
• Commercial Laboratories
• Others

Global Yersinia Diagnostics Market Size & CAGR (2025-2032)

• North America (Product, Diagnostic Test, Technology, End User)
  • US
  • Canada
• Europe (Product, Diagnostic Test, Technology, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Diagnostic Test, Technology, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Diagnostic Test, Technology, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Diagnostic Test, Technology, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioAffinity Technologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gen-Probe Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations